Literature DB >> 16144907

ERCC1 and clinical resistance to platinum-based therapy.

Eddie Reed1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16144907     DOI： 10.1158/1078-0432.CCR-05-1083

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  47 in total

1.  Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.

Authors:  Seong Hyun Jeong; Jae Ho Han; Jang Hee Kim; Mi Sun Ahn; Yoon Ho Hwang; Hyun Woo Lee; Seok Yun Kang; Joon Seong Park; Jin-Hyuk Choi; Kwang Jae Lee; Seung Soo Sheen; Ho-Yeong Lim
Journal:  Dig Dis Sci       Date:  2010-05-26       Impact factor: 3.199

2.  Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer.

Authors:  Mary A Bewick; Robert M Lafrenie; Michael S C Conlon
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-28       Impact factor: 4.553

3.  Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.

Authors:  Rujiao Liu; Xiaoying Zhao; Xin Liu; Zhiyu Chen; Lixin Qiu; Ruixuan Geng; Weijian Guo; Guang He; Jiliang Yin; Jin Li; Xiaodong Zhu
Journal:  Tumour Biol       Date:  2015-08-28

4.  A bifunctional platinum(II) antitumor agent that forms DNA adducts with affinity for the estrogen receptor.

Authors:  Eunsuk Kim; Peter T Rye; John M Essigmann; Robert G Croy
Journal:  J Inorg Biochem       Date:  2008-10-26       Impact factor: 4.155

5.  Effects of geometric isomerism and anions on the kinetics and mechanism of the stepwise formation of long-range DNA interstrand cross-links by dinuclear platinum antitumor complexes.

Authors:  Junyong Zhang; Donald S Thomas; Susan J Berners-Price; Nicholas Farrell
Journal:  Chemistry       Date:  2008       Impact factor: 5.236

6.  Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1.

Authors:  Rui Gao; Douglas K Price; Tristan Sissung; Eddie Reed; William D Figg
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

Review 7.  ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.

Authors:  Ming Yin; Jingrong Yan; Eva Martinez-Balibrea; Francesco Graziano; Heinz-Josef Lenz; Hyo-Jin Kim; Jacques Robert; Seock-Ah Im; Wei-Shu Wang; Marie-Christine Etienne-Grimaldi; Qingyi Wei
Journal:  Clin Cancer Res       Date:  2011-01-28       Impact factor: 12.531

8.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.

Authors:  Roel G W Verhaak; Pablo Tamayo; Ji-Yeon Yang; Diana Hubbard; Hailei Zhang; Chad J Creighton; Sian Fereday; Michael Lawrence; Scott L Carter; Craig H Mermel; Aleksandar D Kostic; Dariush Etemadmoghadam; Gordon Saksena; Kristian Cibulskis; Sekhar Duraisamy; Keren Levanon; Carrie Sougnez; Aviad Tsherniak; Sebastian Gomez; Robert Onofrio; Stacey Gabriel; Lynda Chin; Nianxiang Zhang; Paul T Spellman; Yiqun Zhang; Rehan Akbani; Katherine A Hoadley; Ari Kahn; Martin Köbel; David Huntsman; Robert A Soslow; Anna Defazio; Michael J Birrer; Joe W Gray; John N Weinstein; David D Bowtell; Ronny Drapkin; Jill P Mesirov; Gad Getz; Douglas A Levine; Matthew Meyerson
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

9.  ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.

Authors:  Matthias Villalobos; Piotr Czapiewski; Niels Reinmuth; Jürgen R Fischer; Stefan Andreas; Cornelius Kortsik; Monika Serke; Martin Wolf; Petra Neuser; Alexander Reuss; Philipp A Schnabel; Michael Thomas
Journal:  Med Oncol       Date:  2018-06-15       Impact factor: 3.064

10.  Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

Authors:  W Chua; D Goldstein; C K Lee; H Dhillon; M Michael; P Mitchell; S J Clarke; B Iacopetta
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.